Altered states

Share on facebook
Share on linkedin
Share on twitter
Share on print
Share on email

Once considered a criminal enterprise, the cannabis landscape continues to evolve rapidly, as a growing number of nations and US states move to legalise the mind-altering drug for medicinal and recreational purposes. However, within the US, despite the many states that have decriminalised marijuana, the drug remains federally illegal. Under the Controlled Substances Act, marijuana is currently classified as a Schedule 1 drug—deemed to have no accepted medical applications. Its status as a controlled substance at the federal level poses the primary headwind for emergent business models within the industry for both recreational and medicinal players.

However, momentum is building in Washington DC, as US lawmakers consider easing federal regulations and allowing financial institutions to offer services to the cannabis industry without the risk of repercussions. While the emerging legal landscape of the cannabis industry faces a unique set of challenges, it also presents a myriad of opportunities. Research efforts are under way to provide health care providers and payers with data sets supporting the efficacy of medical marijuana products, which could transform the industry. Whether for medicinal or recreational purposes, cannabis is becoming increasingly more mainstream, as more and more people, across all demographics, are finding ways to incorporate it into their everyday lives.

Raphael J. Lewis and Jack Encarnacao, research analysts at Newton Investment Management

Please note the content on this website is for Investment Professionals only and should be shared responsibly. No other persons should rely on the information contained within this website.

Investment Managers are appointed by BNY Mellon Investment Management EMEA Limited (BNYMIM EMEA), BNY Mellon Fund Managers Limited (BNYMFM), BNY Mellon Fund Management (Luxembourg) S.A. (BNY MFML) or affiliated fund operating companies to undertake portfolio management activities in relation to contracts for products and services entered into by clients with BNYMIM EMEA, BNY MFML or the BNY Mellon funds.

Related reading

Subscribe to updates

1177252 Exp: 16 November 2023